United States Glioblastoma Multiforme Market valuation $6.81 billion by 2033 - Exclusive Report by DatamIntelligence

"The global glioblastoma multiforme market reached US$ 2.68 billion in 2023, with a rise to US$ 2.92 billion in 2024, and is expected to reach US$ 6.81 billion by 2033, growing at a CAGR of 9.6% during the forecast period 2025-2033." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/glioblastoma-multiforme-market?sp

United States: Recent Industry Developments

✅ In September 2025, Bristol Myers Squibb initiated a Phase 2 clinical trial for a novel immunotherapy targeting Glioblastoma Multiforme. The therapy aims to enhance immune cell infiltration in tumors. It represents a next-generation approach for aggressive brain cancers.

✅ In August 2025, Novocure expanded its Optune device availability across 15 new U.S. oncology centers. The device delivers tumor-treating fields to GBM patients, improving progression-free survival. The expansion addresses growing demand for non-invasive GBM therapies.

✅ In July 2025, Roche invested $150 million in a research program focused on antibody-drug conjugates for GBM. The program targets tumor-specific markers to improve treatment efficacy. It strengthens the U.S. oncology pipeline for aggressive brain cancers.

✅ In June 2025, Memorial Sloan Kettering Cancer Center launched a collaborative initiative with a biotech startup to develop CAR-T cell therapies for GBM. The program emphasizes personalized approaches for recurrent tumors. It supports innovation in advanced neuro-oncology treatments.

Japan: Recent Industry Developments

✅ In September 2025, Eisai Co., Ltd. started a Phase 1 trial of a first-in-class GBM-targeted therapy using oncolytic viruses. The therapy is designed to selectively attack tumor cells while sparing healthy tissue. It aligns with Japan's precision oncology goals.

✅ In August 2025, Takeda Pharmaceutical invested in AI-driven drug discovery for GBM treatments. The initiative accelerates identification of novel compounds with higher blood-brain barrier penetration. It strengthens Japan's capabilities in neuro-oncology research.

✅ In July 2025, Kyoto University Hospital launched a multicenter study on combination therapy using immunotherapy and radiotherapy for GBM. The study aims to improve survival rates in recurrent and resistant cases. It enhances clinical knowledge of integrated treatment strategies.

✅ In June 2025, Sumitomo Dainippon Pharma partnered with a biotech startup to develop targeted small-molecule inhibitors for GBM. The collaboration focuses on precision therapies for aggressive brain tumors. It supports Japan's mission for innovative oncology solutions.

Glioblastoma Multiforme Market: Drivers

The glioblastoma multiforme (GBM) therapeutics market is witnessing growth due to the high prevalence and aggressive nature of this primary brain tumor, which necessitates advanced and effective treatment options. Therapies including surgery, radiotherapy, chemotherapy, targeted therapies, and emerging immunotherapies aim to improve patient survival, manage tumor progression, and enhance quality of life. Rising awareness of early diagnosis, clinical trials, and personalized treatment approaches is driving demand for innovative GBM therapeutics. Technological advancements in precision medicine, molecular targeting, gene therapy, and nanotechnology-based drug delivery are improving treatment efficacy and minimizing side effects. Additionally, increasing investments from pharmaceutical companies, research institutions, and government initiatives are supporting the development of novel therapies.

Innovation in immunotherapy, oncolytic viruses, and combination treatment strategies is enabling more effective management of GBM and providing hope for improved patient outcomes. Integration with advanced imaging techniques, biomarkers, and AI-driven diagnostic tools is enhancing patient stratification, monitoring, and therapeutic decision-making. Growing focus on improving survival rates, reducing recurrence, and addressing unmet medical needs is further boosting demand for targeted therapies. Collaborations between biotech firms, academic institutions, and healthcare providers are accelerating research, clinical development, and commercialization of cutting-edge treatment options. Collectively, these factors are driving steady growth in the glioblastoma multiforme therapeutics market as stakeholders increasingly prioritize innovative, personalized, and effective treatment strategies.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/glioblastoma-multiforme-market?sp

Glioblastoma Multiforme Market: Major Players

Genentech (Roche), Pfizer Inc., Amgen Inc., Merck & Co., Inc., VBI Vaccines Inc. and Starlight Therapeutics, among others.

Segment Covered in the Glioblastoma Multiforme Market:

➥ By Product Type: Radiation Therapy, Chemotherapy, Immunotherapy, Surgery, Others

➥ By Drugs: Temozolomide, Lomustine, Bevacizumab, Others

➥ By Distribution Channel: Hospitals, Specialty Clinics, Others

Research Process:

Both primary and secondary data sources have been used in the Glioblastoma Multiforme Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Glioblastoma Multiforme Market Research Industry:

➠ Who leads the Glioblastoma Multiforme industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Glioblastoma Multiforme market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Glioblastoma Multiforme market growth?
➠ What are the dominant sales and distribution strategies in the Glioblastoma Multiforme industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=glioblastoma-multiforme-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.